Skip to main content
Clinical Trials/ACTRN12622000551796
ACTRN12622000551796
Recruiting
N/A

High flow humidified nasal oxygen for prevention of hypoxaemia associated with remifentanil patient controlled analgesia (PCA) in labouring people – a safety and feasibility study

Department of Anaesthesia, The Royal Women's Hospital - Parkville0 sites40 target enrollmentApril 8, 2022

Overview

Phase
N/A
Intervention
Not specified
Conditions
Pregnancy
Sponsor
Department of Anaesthesia, The Royal Women's Hospital - Parkville
Enrollment
40
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 8, 2022
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Department of Anaesthesia, The Royal Women's Hospital - Parkville

Eligibility Criteria

Inclusion Criteria

  • People (20 in each group) in labour, expecting live birth, term pregnancy more than or equal to 37 weeks gestation, singleton pregnancy, no cardiac or respiratory disease, no previous caesarean section

Exclusion Criteria

  • Second stage of labour, significant nasal pathology, severe systemic disease (American Society of Anesthesiologists (ASA) physical status score of 3 or more), preeclampsia or sepsis, opioid allergy, inability to understand protocol instructions, substance abuse disorder, any administration of intramuscular opioid in the last 24 hours

Outcomes

Primary Outcomes

Not specified

Similar Trials